LIV-2008 monoclonal antibodies (LivTech/Yakult Honsha)

N/A

Report date: 2025/03/20 16:08:25

Base Information

Drug NameLIV-2008 monoclonal antibodies (LivTech/Yakult Honsha)
Drug Alias NameLIV-2008 monoclonal antibodies (LivTech)anti-TROP-2 humanized mAbs (LivTech)LIV-2008b
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor-associated calcium signal transducer 2 modulators
TargetsTumor-associated calcium signal transducer 2
Therapy Area/IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanMacauHong Kong +[5] 
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesLivTech Inc
China Registration ClassN/A

Develop Information

Active CompaniesChiome Bioscience Inc
Inactive CompaniesYakult Honsha Co LtdLivTech IncShanghai Henlius Biotech Inc
Active IndicationsSolid tumoursLung NeoplasmsPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A